EP3164711A4 - Specific biomarker set for non-invasive diagnosis of liver cancer - Google Patents

Specific biomarker set for non-invasive diagnosis of liver cancer Download PDF

Info

Publication number
EP3164711A4
EP3164711A4 EP14896556.9A EP14896556A EP3164711A4 EP 3164711 A4 EP3164711 A4 EP 3164711A4 EP 14896556 A EP14896556 A EP 14896556A EP 3164711 A4 EP3164711 A4 EP 3164711A4
Authority
EP
European Patent Office
Prior art keywords
liver cancer
specific biomarker
invasive diagnosis
biomarker set
invasive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14896556.9A
Other languages
German (de)
French (fr)
Other versions
EP3164711A1 (en
Inventor
Cornelia Wing Yin MAN
Norman Fung Man WAI
Benjamin Chi Yin WAI
Bing Lou Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dragon Victory Development Ltd
Original Assignee
Dragon Victory Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/321,870 external-priority patent/US9885718B2/en
Priority claimed from US14/321,867 external-priority patent/US9506925B2/en
Application filed by Dragon Victory Development Ltd filed Critical Dragon Victory Development Ltd
Publication of EP3164711A1 publication Critical patent/EP3164711A1/en
Publication of EP3164711A4 publication Critical patent/EP3164711A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
EP14896556.9A 2014-07-02 2014-07-31 Specific biomarker set for non-invasive diagnosis of liver cancer Withdrawn EP3164711A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/321,870 US9885718B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
US14/321,867 US9506925B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
PCT/US2014/049038 WO2016003479A1 (en) 2014-07-02 2014-07-31 Specific biomarker set for non-invasive diagnosis of liver cancer

Publications (2)

Publication Number Publication Date
EP3164711A1 EP3164711A1 (en) 2017-05-10
EP3164711A4 true EP3164711A4 (en) 2018-05-23

Family

ID=55019816

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14896556.9A Withdrawn EP3164711A4 (en) 2014-07-02 2014-07-31 Specific biomarker set for non-invasive diagnosis of liver cancer

Country Status (13)

Country Link
EP (1) EP3164711A4 (en)
JP (2) JP2017520763A (en)
KR (1) KR102086788B1 (en)
CN (2) CN107478842B (en)
AU (2) AU2014399919B2 (en)
CA (1) CA2939912C (en)
HK (2) HK1224370A1 (en)
MY (2) MY179845A (en)
NZ (1) NZ722492A (en)
SG (1) SG11201606106SA (en)
TW (1) TWI700493B (en)
UY (1) UY36200A (en)
WO (1) WO2016003479A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106383231B (en) * 2016-09-02 2020-03-17 四川大学 Marker combination for diagnosing liver cancer and application thereof
KR102175265B1 (en) 2019-03-13 2020-11-06 충남대학교산학협력단 Biomarker composition comprising TXNDC7 for diagnosis or predicting prognosis of hepatocellular carcinoma
CN110646615B (en) * 2019-08-27 2021-07-13 南方医科大学 Biological marker and treatment target of hepatic fibrosis and application thereof
WO2023282916A1 (en) 2021-07-09 2023-01-12 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
CN113502328A (en) * 2021-05-27 2021-10-15 深圳市人民医院 Application of reagent for detecting expression level of marker in sample in preparation of kit for detecting or diagnosing breast cancer
CN113777295B (en) * 2021-09-15 2024-03-19 江南大学 High-sensitivity quantum dot probe for detecting tumor marker PD-L1, preparation method and application
CN113956344A (en) * 2021-10-14 2022-01-21 江南大学 Novel FGF analogue for treating liver cancer and application thereof
CN114113611B (en) * 2021-12-13 2023-07-14 郑州大学 Biomarker for liver cancer diagnosis and detection kit

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040059519A1 (en) * 1998-08-18 2004-03-25 Chandler Van S. Multiplexed analysis of clinical specimens apparatus and methods
WO2004052392A2 (en) * 2002-12-11 2004-06-24 The University Of Birmingham Cancer immunotherapy using polycomb proteins
US20110281284A1 (en) * 2007-08-10 2011-11-17 Otsuka Pharmaceutical Co., Ltd Novel liver cancer marker
WO2013049704A2 (en) * 2011-09-28 2013-04-04 Armune Biosciences, Inc. Method and system of particle-phage epitope complex

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893844B1 (en) * 1998-09-22 2005-05-17 Long Yu DNA encoding a new human hepatoma derived growth factor and producing method thereof
US7387881B2 (en) * 2001-09-19 2008-06-17 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
AU2002361908A1 (en) * 2001-12-31 2003-07-24 Quark Biotech, Inc. Methods for identifying marker genes for cancer
JP3960614B2 (en) * 2003-08-31 2007-08-15 株式会社イムノディア Anti-peptide antibody measurement method and vaccine candidate selection method for peptide vaccine
GB0406215D0 (en) * 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
WO2005123944A1 (en) * 2004-06-18 2005-12-29 Roche Diagnostics Gmbh Use of protein pdx1 as a marker for breast cancer
JP5211315B2 (en) * 2006-07-25 2013-06-12 国立大学法人愛媛大学 Tumor marker, tumor diagnostic kit, and method for measuring tumor marker
US8512963B2 (en) * 2009-11-25 2013-08-20 The Johns Hopkins University Detection and quantitation of full-length thioredoxin (TRX) and truncated thioredoxin (TRX 80) in complex samples
US9523680B2 (en) * 2010-06-30 2016-12-20 Ambergen, Inc. Global Proteomic screening of random bead arrays using mass spectrometry imaging
JP5493130B2 (en) * 2010-08-25 2014-05-14 国立大学法人山口大学 Autoantibody detection method
US20140141986A1 (en) * 2011-02-22 2014-05-22 David Spetzler Circulating biomarkers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040059519A1 (en) * 1998-08-18 2004-03-25 Chandler Van S. Multiplexed analysis of clinical specimens apparatus and methods
WO2004052392A2 (en) * 2002-12-11 2004-06-24 The University Of Birmingham Cancer immunotherapy using polycomb proteins
US20110281284A1 (en) * 2007-08-10 2011-11-17 Otsuka Pharmaceutical Co., Ltd Novel liver cancer marker
WO2013049704A2 (en) * 2011-09-28 2013-04-04 Armune Biosciences, Inc. Method and system of particle-phage epitope complex

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAI LIPING ET AL: "Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma", CLINICAL IMMUNOLOGY, vol. 152, no. 1, 22 March 2014 (2014-03-22), pages 127 - 139, XP028638419, ISSN: 1521-6616, DOI: 10.1016/J.CLIM.2014.03.007 *
KALPA PATEL ET AL: "Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers", INTERNATIONAL JOURNAL OF CANCER, vol. 129, no. 1, 9 November 2010 (2010-11-09), pages 133 - 142, XP055130158, ISSN: 0020-7136, DOI: 10.1002/ijc.25644 *

Also Published As

Publication number Publication date
WO2016003479A1 (en) 2016-01-07
SG11201606106SA (en) 2016-08-30
AU2017232129A1 (en) 2017-10-12
KR102086788B1 (en) 2020-03-09
CA2939912C (en) 2019-04-16
UY36200A (en) 2016-01-29
KR20170021234A (en) 2017-02-27
HK1248803A1 (en) 2018-10-19
JP2017520763A (en) 2017-07-27
JP2020160082A (en) 2020-10-01
AU2014399919A1 (en) 2016-08-11
TW201602579A (en) 2016-01-16
MY179845A (en) 2020-11-18
TWI700493B (en) 2020-08-01
MY195045A (en) 2023-01-04
EP3164711A1 (en) 2017-05-10
CA2939912A1 (en) 2016-01-07
AU2017232129B2 (en) 2018-10-25
NZ722492A (en) 2019-09-27
CN105319362B (en) 2018-07-13
CN107478842A (en) 2017-12-15
CN107478842B (en) 2020-10-16
CN105319362A (en) 2016-02-10
HK1224370A1 (en) 2017-08-18
AU2014399919B2 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
EP3177739A4 (en) Microrna biomarker for the diagnosis of gastric cancer
EP3209382A4 (en) Combination immunotherapy approach for treatment of cancer
EP3268499A4 (en) Methods for diagnosis of sepsis
EP3134436A4 (en) Treatment of h-ras-driven tumors
EP3307243A4 (en) Diagnostic test for early stage cancer
HK1224370A1 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
EP3232198A4 (en) Biomarker for diagnosis of hepatoma and use thereof
EP3427066A4 (en) Lipid biomarkers for the diagnosis of cancer
EP3227686A4 (en) Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
EP3201360A4 (en) Methods for assessing risk of developing breast cancer
EP3123381A4 (en) Compositions and methods related to diagnosis of prostate cancer
EP3139919A4 (en) Compounds for treatment of cancer
EP3134736A4 (en) Use of interleukin-2 for diagnosis of celiac disease
EP3204008A4 (en) Use of biomarkers for predicting clinical sensitivity to cancer treatment
EP3132802A4 (en) Therapeutic agent for solid cancer
EP3089992A4 (en) Compositions and methods for imaging cancer
EP3298145A4 (en) Method of diagnosis of breast cancer
EP3426241A4 (en) Methods of diagnosing cancer
EP3189333A4 (en) Diagnosis of cancer
EP3149209A4 (en) Methods for typing of lung cancer
EP3152195A4 (en) Mth1 inhibitors for treatment of cancer
EP3139956A4 (en) Methods of using anti-ang2 antibodies
EP3191846A4 (en) Methods of detecting prostate cancer
EP3347051A4 (en) Sequencing-directed selection of tumor theranostics
EP3325972A4 (en) Biomarker combinations for prostate disease

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/574 20060101AFI20171212BHEP

Ipc: G01N 33/564 20060101ALI20171212BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1237873

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20180420

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/574 20060101AFI20180416BHEP

Ipc: G01N 33/564 20060101ALI20180416BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190415

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230726

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1237873

Country of ref document: HK